Keyphrases
Academy
9%
Autoantibodies
6%
Autoimmune Neuropathy
9%
Cerebrospinal Fluid
6%
Chronic Inflammatory Demyelinating Polyneuropathy
100%
Chronic Inflammatory Demyelinating Polyradiculoneuropathy
34%
Clinical Assessment
6%
Clinical Features
8%
Clinical Practice
5%
Demyelinating Neuropathy
8%
Diagnostic pitfalls
10%
Disability
19%
Disability Evaluation
5%
Disease Activity
7%
Disease Burden
8%
Electrodiagnosis
9%
Functional Status
5%
Global Survey
8%
Grip Strength
9%
Hizentra
13%
Hypereosinophilic Syndrome
13%
Immune Response
8%
Immunoglobulin
8%
Immunoglobulin Therapy
6%
Inflammatory Neuropathy
8%
Intravenous Immunoglobulin (IVIg)
28%
Intravenous Immunoglobulin Therapy
7%
Joint Task
8%
Myasthenia Gravis
12%
Myelin-associated Glycoprotein
8%
Nerve
5%
Nerve Conduction Studies
5%
Neurologist
7%
Neurology
9%
Neuropathy
26%
Peripheral Nerve
17%
Phase II Study
8%
Placebo
11%
Placebo-controlled
9%
Plasmid DNA (pDNA)
8%
Polyneuropathy
14%
Quality of Life
6%
Randomized Double-blind
8%
Randomized Placebo-controlled Trial
5%
Routine Care
5%
Society Guidelines
9%
Subcutaneous Immunoglobulin
15%
Treatment Response
7%
Treatment-related Fluctuation
8%
Tryptophan
5%
Medicine and Dentistry
Biological Marker
7%
Cerebrospinal Fluid
7%
Chronic Inflammatory Demyelinating Polyneuropathy
62%
Clinical Assessment
5%
Clinician
5%
Diagnosis
21%
Diagnostic Error
16%
Disease
15%
Disease Course
5%
Electrodiagnosis
5%
Eosinophilia Myalgia Syndrome
8%
Immunity
7%
Immunoglobulin
26%
Immunotherapy
9%
Maintenance Therapy
6%
Myelin Associated Glycoprotein
7%
Neurology
9%
Neuropathy
39%
Peripheral Nerve
13%
Placebo
8%
Polyneuropathy
10%
Polyradiculoneuropathy
17%
Retrospective Study
5%
Treatment Response
5%
Tryptophan
5%